US drug developer Novavax Inc said on Monday that it is starting a mid-stage study of its experimental Covid-19 vaccine in South Africa, as the country experiences a surge in coronavirus cases. The Phase 2B trial study of NVX-CoV2373 will be conducted on about 2,665 healthy adults and will evaluate the safety and immunogenicity in about 240 medically stable, HIV-positive adults, the company said in a statement.
from Engineering News | Home https://ift.tt/3iO8SWl
